Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
| (6,594.98%) | (404.48%) | (238.26%) | (195.46%) |
+8 more TTM periods Free account |
|
| (56.45%) | (53.81%) | (52.78%) | (80.40%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(370.71%) | (224.73%) | (184.42%) | (335.41%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(18.61) | (19.31) | (32.02) | (42.88) | |
Free Cash Flow |
(28.90) | (34.14) | (43.20) | (56.40) | |
Capital Expenditures |
(0.04) | 0.01 | (0.19) | — | |
Piotroski F-Score |
2.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(557.55%) | (192.62%) | (136.94%) | (158.39%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,625.88% | 3,399.17% | 2,889.61% | 2,565.74% | |
Selling, General and Administrative Expense of Revenue |
2,899.50% | 2,102.17% | 1,858.18% | 1,345.65% | |
Share Based Compensation of Revenue |
586.68% | 618.67% | 671.30% | 453.92% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 1.04 | 1.11 | 0.71 | |
Depreciation/Fixed assets |
0.44 | 0.22 | (0.19) | (0.69) | |
Capex/Depreciation |
(0.09) | 0.02 | 0.86 | 0.00 | |
Revenue per Share |
0.26 | 0.34 | 0.57 | 0.90 | |
Operating CF per Share |
(18.58) | (19.31) | (31.88) | (42.88) | |
Capex per Share |
(0.03) | 0.00 | (0.14) | 0.00 | |
Capex to Sales |
0.10 | (0.01) | 0.25 | 0.00 | |
Net Profit Margin |
(7,266.08%) | (5,491.17%) | (5,043.64%) | (6,711.39%) |
Columns are period end dates